Acalabrutinib, an anti-cancer drug is a member of a family of drugs called anthocyanins and has a novel mechanism of action. The mechanism of action of acalabrutinib is by increasing the intracellular acidity of the cancer cells in cancer cachexia.
Cachexia is a condition where the body does not have sufficient quantities of vital nutrients. This causes the cancer cells to shrink and eventually die in most cases, although the survival rate of the affected patients can be improved with further therapy. Treatment of primary outcome measures includes Acalabrutinib, 100 mg twice a day, with a standard of care, R-CHOP chemotherapy with IV every 14 days for an extended period of six months.
In secondary outcome measure, patients are monitored at least for 28 days after the last dose of Acalabrutinib. At this point in time, if the disease progression or occurrence of any new symptoms is noted, additional therapy will be required. Patients who undergo additional therapy are more likely to survive than patients who do not receive additional treatment. In patients who have reached the age of 65 and above, treatment is usually performed as maintenance therapy.
Acalabrutinib can be used for treatment of acute Myelogenouscardia (inflammation of the heart muscle and associated with sudden death) and gastric ulcer. It has been shown to delay the progression of gastric ulcer and associated bleeding associated with it.
Acalabrutinib is also effective in the treatment of atrial fibrillation, a heart rhythm abnormality that occurs due to genetic programming and is associated with both heart disease and stroke. Acalabrutinib is also indicated in the treatment of acute dyspnea and chronic obstructive pulmonary disease as well as the treatment of refractory cardiomyopathy. At the present time, no known side effects occur with the use of acalabrutinib.
The primary outcome measures of the study treatment are cardiorespiratory efficiency at the end of the initial period of treatment and during the follow-up period. The secondary outcome measures consist of changes in the frequency and magnitude of the adverse events. An additional objective measure of lung function was also included in the study. The study did not investigate the safety of the drug or the metabolism of acetylcholine.
A short-term safety analysis suggested no significant changes in the pharmacokinetics or kinetics of acalabrutinib in patients receiving single doses up to 500 mg/day. There were no significant changes in the blood pressure, heart rate, or respiratory rate in patients receiving this therapy.
A study drug study coordinator who was involved in the study stated that the first dose of acalabrutinib does not produce any adverse events. He stated that further studies are needed to assess the safety of this new anti-diuretic. He stated that further studies should be performed on other patients who receive this therapy in the future to determine its long-term use. You can contact us for more information.